Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study)

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2175-2181

  Rijkaart, Dorien C ^a,b   Berkhof, Johannes ^a   Van Kemenade, Folkert J ^a   Rozendaal, Lawrence ^a   Verheijen, René H M ^c   Bulk, Saskia ^c   Herreilers, Miriam E ^b   M Verweij, Wim ^b   Snijders, Peter J F ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SALTRO   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Borderline nuclear abnormality; Cervical intraepithelial neoplasia; Cervical screening; CIN; Colposcopy; Human papillomavirus; Low grade abnormalities; Management; Mild dyskaryosis

Indexed keywords

ADULT; ALGORITHM; ARTICLE; COLPOSCOPY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CYTOLOGY; DYSKARYOSIS; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERVENTION STUDY; NETHERLANDS; POPULATION; PRIORITY JOURNAL; SAMPLE; SCREENING; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; VIRUS EXAMINATION; WART VIRUS; COHORT ANALYSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PATIENT REFERRAL; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; ALGORITHMS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COLPOSCOPY; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; REFERRAL AND CONSULTATION; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77949907260     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24891     Document Type: Article

References (26)

1. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-1876
2. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001;195:300-306
3. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-1623
4. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, Roth P, Lorincz AT, Gafni A, Walter SD. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med 2003;127: 1169-1175
5. Dietsch E, Davies C. The nocebo effect for women in waiting. Collegian 2007;14:9-14.
6. Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J. Management of the low-grade abnormal Pap smear: what are women's preferences? J Fam Pract 2002;51: 849-855
7. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-293 (Pubitemid 38256273)
8. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, Roth P, Lorincz AT, Gafni A, Walter SD. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med 2003;127: 1169-1175
9. Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJF, Verheijen RHM, Meijer CJLM. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006;118:1759-1768
10. Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006;332:83-85 (Pubitemid 43099248)
11. van Kemenade FJ, Wiersma T, Helmerhorst TJ. [New version of the pathology practice guideline for cervical cytology: sharpened criteria for adequacy; expanded use of new techniques]. Ned Tijdschr Geneeskd 2007;151:1283-1286
12. Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002;46:619-629
13. National Health Service Screening Programme. (NHSCSP publication 1. Sheffield: NHS Cancer Screening Programmes; 2000), 1-36. 2009.
14. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57:388-393
15. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5\+/6\+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006;44:3680-3685
16. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenemans P, Helmerhorst TJ. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000;107:600-604
17. Anderson MC. Premalignant and malignant squamous lesions of the cervix. In: Fox H, Wells M, Haines, Taylor, eds. Obstetrical and gynaecological pathology. New York: Chruchill Livingstone, 1995.292-297
18. Hopman EH, Voorhorst FJ, Kenemans P, Meyer CJ, Helmerhorst TJ. Observer agreement on interpreting colposcopic images of CIN. Gynecol Oncol 1995; 206-209
19. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Rotterdam: Erasmus, MC, 2006.
20. van Ballegooijen M, Koopmanschap MA, Tjokrowardojo AJ, van Oortmarssen GJ. Care and costs for advanced cervical cancer. Eur J Cancer 1992;28A:1703-1708
21. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and costeffectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96: 604-615
22. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-2381
23. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.
24. Cuzick J. Role of HPV testing in clinical practice. Virus Res 2002;89:263-269
25. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007;109:1325-1331
26. Rebolj M, Bais AG, van BM, Boer R, Meerding WJ, Helmerhorst TJ, Habbema JD. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: comparison of costs and side effects of three alternative strategies. Int J Cancer 2007;121:1529-1535